Deerfield Management AGL Position
ExitedDeerfield Management exited their position in agilon health, inc. (AGL) in Q2 2024, after holding the stock for 2 quarters.
The position was first reported in Q1 2024 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds AGL.
Short interest stands at 13.1% of float with 7.0 days to cover, indicating significant bearish positioning against the stock.
About agilon health, inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
Full company profile →Short Interest
13.1%
7.0 days to cover
Deerfield Management AGL Position History
Frequently Asked Questions
Does Deerfield Management own AGL?
No. Deerfield Management exited their position in agilon health, inc. (AGL) in Q2 2024. They previously held the stock for 2 quarters.
How many hedge funds own AGL?
1 specialist biotech hedge fund currently holds AGL, including Rock Springs Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy AGL?
Deerfield Management's position in AGL was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's AGL position increasing or decreasing?
Deerfield Management completely exited their AGL position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AGLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →